Covidien releases results from a pair of studies supporting treatment of peripheral artery disease with the EverFlex self-expanding stent combined with directional atherectomy and a drug-coated balloon.
Massachusetts medical device giant Covidien (NYSE:COV) released results from a pair of studies, supporting use of the company’s EverFlex self-expanding stent and combining directional atherectomy with drug-coated balloons in treatment of patient with peripheral artery disease.
The company says its findings suggest a “new approach” to treating limb blockages in patients with PAD, a condition that affects more than 200 million patients around the world.
